Tyrosine kinase inhibitorFDA-approvedSecond-line
Dasatinib
How it works
Blocks the BCR-ABL tyrosine kinase enzyme, which is overactive in CML cells, and also inhibits other tyrosine kinases involved in cancer growth.
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
In clinical trials, around 70% of patients achieved a major cytogenetic response, with a median progression-free survival of approximately 20 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Trial to Improve Treatment for Children with T-Cell Leukemia or Lymphoma | Leukemia | phase-2 | — | Source → |
| New Treatment Combination for Chronic Myeloid Leukemia Being Tested | Leukemia | phase-2 | — | Source → |
| PPIs May Affect Leukemia Treatment | Leukemia | observational | — | Source → |
| Combining blinatumomab and dasatinib for pediatric leukemia treatment | Leukemia | observational | At a median follow-up of 13 months, all patients were alive without disease relapse. | Source → |
| Testing Blinatumomab and Tyrosine Kinase Inhibitor Therapy for Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Chronic Leukemia Relapse After Bone Marrow Transplantation | Leukemia | observational | — | Source → |
| Improving Cancer Treatment with Targeted Drug Delivery | Leukemia | lab-study | — | Source → |
| Combining Dasatinib with Chemotherapy in Leukemia Treatment | Leukemia | phase-2 | The overall MRD negativity rate was 62.5%. | Source → |
| Rare Complication in Cancer Patients on Dasatinib Therapy | Leukemia | observational | — | Source → |
| Woman Develops Lung Injury After Taking Cancer Drug Dasatinib | Leukemia | observational | — | Source → |
| Dasatinib May Harm Blood Vessels, Study Suggests | Leukemia | lab-study | — | Source → |
| Dasatinib Side Effect Study in CML Patients | Leukemia | observational | A change in TKI to bosutinib was associated with a 46% risk of recurrence of PE in patients who develop PE on dasatinib. | Source → |
| Combining CBD and dasatinib may help treat lung cancer | Lung Cancer | lab-study | The combination of CBD and low-dose dasatinib exhibited a ZIP of > 10, indicating significant synergistic apoptosis. | Source → |
| Dasatinib and Low-Intensity Chemotherapy for a Rare Blood Cancer | Leukemia | phase-2 | The estimated 3-year disease-free survival was 52.4% and overall survival was 73.2%. | Source → |
| New Treatment Approach for Adult Leukemia Shows Promise | Leukemia | phase-3 | Disease-free survival, overall survival, and event-free survival are 75.8%, 80.7%, and 74.6%, respectively. | Source → |
| Dasatinib Dosage May Need to Be Adjusted for Chinese Patients with CML | Leukemia | lab-study | — | Source → |
| Targeted Cancer Treatment Using Gold Nanoparticles and Dasatinib | Breast Cancer | lab-study | The IC value for the BT-474 cells decreased from 6.95 μM to 2.57 μM, while for the MCF-7 cells, it decreased from 13.97 μM to 8.57 μM. | Source → |
| Combining Two Drugs May Help Treat Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Tyrosine Kinase Inhibitors Affect Platelet Function in Lab Experiments | Leukemia | lab-study | — | Source → |
| Dasatinib Effective in Rare Leukemia Case | Leukemia | observational | Remission was achieved with the second-generation tyrosine kinase inhibitor (TKI) dasatinib, and the response has been sustained for 10 months. | Source → |
| Ponatinib and Dasatinib Compared in Leukemia Patients with Brain Relapse | Leukemia | observational | The total CR (complete remission) rate was 90.5%. | Source → |
| Comparing Cancer Treatments in Chinese Children | Leukemia | phase-3 | — | Source → |
| Low-Dose Dasatinib Shows Promise in Treating Chronic Myeloid Leukemia | Leukemia | observational | At 12 months, 68% and 66.6% patients achieved major molecular response in dasatinib 50mg and imatinib groups respectively. | Source → |
| Identifying Proteins That Interact with Cancer Drugs in Live Cells | Leukemia | lab-study | — | Source → |
| Gastrointestinal Bleeding Risk with Cancer Medications | Leukemia | observational | — | Source → |
| Monitoring Drug Levels May Reduce Chest Fluid Buildup in Leukaemia Patients | Leukemia | phase-2 | The cumulative incidence of pleural effusion was 4% in the TDM arm compared to 15% in the control arm. | Source → |
| Rare Cancer Treated with Combination Therapy | Leukemia | observational | — | Source → |
| Dasatinib Therapy Affects Heart Function in CML Patients | Leukemia | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.